title: The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma.
abstract: To compare the clinical effects of different cycles of carboplatin, etoposide, and vincristine (CEV) regimens of adjuvant chemotherapy in postenucleation high-risk patients with IRSS Stage I retinoblastoma (RB).
  
  
  
  A retrospective analysis of 53 RB patients hospitalized in the Zhongshan Ophthalmic Center of Sun Yat-sen University was performed. All patients had unilateral involvement, received enucleation treatment, were diagnosed as RB by pathology, and had high-risk pathological factors. Patients either refused postoperative chemotherapy or received three or six cycles of CEV regimen chemotherapy. The clinical information, treatment, and results of patients in all groups were compared.
  
  
  
  A total of 19 cases refused postenucleation chemotherapy, 18 cases received three cycles, and 16 cases received six cycles of the CEV regimen chemotherapy. The 5-year disease-free survival rate and the overall survival (OS) rate in the chemotherapy group were higher than those in the non-chemotherapy group (97.1% vs. 63.2%, p = 0.001) and were not different between the three-cycle chemotherapy group and the six-cycle chemotherapy group (94.4% vs. 100%, p = 0.35).
  
  
  
  After eye enucleation for patients with high-risk unilateral RB, the CEV regimen chemotherapy was associated with a higher survival rate. The three-cycle CEV regimen adjuvant chemotherapy was effective and is expected to replace the six-cycle CEV regimen chemotherapy.
authors.affiliation: a State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou , China.
authors.forename: Huijing
authors.initials: H
authors.lastname: Ye
authors.affiliation: b Department of Ophthalmology , The First Affiliated Hospital of Guangxi Medical University , Nanning , Guangxi , China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Du
authors.affiliation: a State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou , China.
authors.forename: Rongxin
authors.initials: R
authors.lastname: Chen
authors.affiliation: c Affiliated Hospital of Zunyi Medical College , Zunyi , Guizhou , China.
authors.forename: Xin
authors.initials: X
authors.lastname: Luo
authors.affiliation: a State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou , China.
authors.forename: Yuxiang
authors.initials: Y
authors.lastname: Mao
authors.affiliation: a State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou , China.
authors.forename: Siming
authors.initials: S
authors.lastname: Ai
authors.affiliation: a State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou , China.
authors.forename: Wenfang
authors.initials: W
authors.lastname: Ma
authors.affiliation: a State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou , China.
authors.forename: Yungang
authors.initials: Y
authors.lastname: Ding
authors.affiliation: a State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou , China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.affiliation: a State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou , China.
authors.forename: Huasheng
authors.initials: H
authors.lastname: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage*; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage*; D015353:Eye Enucleation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011182:Postoperative Care / Q000379:methods*; D019572:Retinal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D012175:Retinoblastoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D014750:Vincristine; D005047:Etoposide; D016190:Carboplatin
keywords: Chemotherapy; clinical result; cycles; high-risk; retinoblastoma